RA
CLSD

Rosalind Advisors’s Clearside Biomedical CLSD Stock Holding History

Rosalind Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,481
Closed -$162K – 43
2024
Q3 		$162K Sell
8,481
-164,359
-95% -$2.81M 0.1% 32
2024
Q2 		$3.37M Hold
172,840
– – 2.59% 18
2024
Q1 		$3.97M Buy
+172,840
New +$3.73M 3.71% 13

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rosalind Advisors's CLSD Position: Q4 2024 in Review

Rosalind Advisors sold out of Clearside Biomedical (CLSD) in Q4 2024, closing a stake of 8,481 shares — an estimated $162K sold.

Rosalind Advisors first reported a position in CLSD in Q1 2024 and held it in 3 quarters. The position peaked at $3.97M in Q1 2024. 43 funds tracked by Wall St. Rank hold CLSD as of Q4 2024.

  • Rosalind Advisors reported no remaining Clearside Biomedical position as of Q4 2024 after selling out during the quarter.
  • Rosalind Advisors sold 8,481 Clearside Biomedical shares in Q4 2024, an estimated $162K.
  • Rosalind Advisors first reported a position in Clearside Biomedical in Q1 2024 and held it in 3 quarters.
  • Rosalind Advisors's Clearside Biomedical position peaked at $3.97M in Q1 2024.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.